Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25161266 | 0.86 | HDAC1 (0.58) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161315 | 0.85 | HDAC1 (0.51) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161231 | 0.85 | HDAC2 (0.58) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161237 | 0.84 | HDAC1 (0.48) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161246 | 0.83 | HDAC2 (0.57) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161760 | 0.83 | HDAC1 (0.47) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161114 | 0.82 | HDAC2 (0.51) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL25161778 | 0.82 | HDAC2 (0.51) | HDAC1HDAC2HDAC3KCNH2CYP1A2 | |
| SCHEMBL23517831 | 0.82 | HDAC1 (0.53) | HDAC1HDAC2HDAC3 | |
| SCHEMBL23517747 | 0.81 | SMN1; SMN2 (0.54) | HDAC1HDAC2HDAC3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119479-A1 | A HISTONE DEACETYLASE INHIBITOR HAVING A NITROGEN-CONTAINING AROMATIC HETEROCYCLYL GROUP | SHIONOGI & CO., LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119479-A1 | A HISTONE DEACETYLASE INHIBITOR HAVING A NITROGEN-CONTAINING AROMATIC HETEROCYCLYL GROUP | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.